• Home
  • About
    • Overview
    • Sharing Data
    • ORCID
  • Help
  • History (1)
    • Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
    • See All Pages
  • search
    • Find People
    • Find Everything
Login to edit your profile (add a photo, awards, links to other websites, etc.)
  • Edit My Profile
  • My Person List (0)

Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?

Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer. 1996 May 01; 77(9):1854-61.

View in: PubMed

subject areas
  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Carcinoma
  • Cost-Benefit Analysis
  • Disease Progression
  • Flutamide
  • Focus Groups
  • Health Care Costs
  • Humans
  • Male
  • Meta-Analysis as Topic
  • Models, Economic
  • Multicenter Studies as Topic
  • National Institutes of Health (U.S.)
  • Orchiectomy
  • Policy Making
  • Prostatic Neoplasms
  • Quality of Life
  • Survival Rate
  • Treatment Outcome
  • United States
  • Value of Life

authors with profiles
  • Charles Lee Bennett